Medications for risk reduction of primary breast cancer in women: US preventative services task force recommendation statement. Annals of internal medicine, Nov. 2013, Vol. 159(10), p.698-708.
Moyer, V.A., et al.
http://annals.org/article.aspx?articleid=1770699
The USPSTF reviewed evidence on the effectiveness, adverse effects, and subgroup variations of medications to reduce the risk for breast cancer—specifically, the selective estrogen receptor modulators tamoxifen and raloxifene. The USPSTF also reviewed a meta-analysis of placebo-controlled trials to understand the relative benefits and harms of tamoxifen and raloxifene. The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer.
